An integrated bioinformatics approach for identifying genetic markers that predict cerebrospinal fluid biomarker p-tau181/Aβ1-42 ratio in ApoE4-negative mild cognitive impairment patients
Manuscript Number:
14-2118R2
Author(s):
Anders Bresell, Kina Höglund, Thibaud Lebouvier, Mattias Rantalainen, Hugh Salter, Ying Sun
Disclosures
Anders Bresell
Nothing to Disclose
Kina Höglund
Nothing to Disclose
Thibaud Lebouvier
Nothing to Disclose
Mattias Rantalainen
Nothing to Disclose
Hugh Salter
Equity:
Shareholder in AstraZeneca AB c 20000 USD
Sponsors:
Former employee of AstraZeneca AB, employed during the course of this research
Ying Sun
Sponsors:
I am employed as post-doctoral research fellow by AstraZeneca, a pharmaceutical company.